J Neurosurg 143:1530–1538, 2025
This clinical study analyzes recurrence after angiographic cure of intracranial dural arteriovenous fistulas (DAVFs) using a single-center DREAM-INI cohort of 510 patients. It reports an overall recurrence rate of 8.0%, estimated cumulative recurrence of 13.9% at 36 months and 24.1% at 105 months, and an annual recurrence risk of 6.2%, with most recurrences occurring within 15 months but some delayed beyond 10 years.
The paper identifies independent risk factors including age <45 years, transverse–sigmoid sinus location, multiple fistulae, pial arterial supply, and venous congestion, distinguishes in situ versus remote-site recurrence, explores pathophysiologic mechanisms (venous hypertension, incomplete embolization, angiogenesis), and recommends angiographic follow-up beyond one year for high-risk cured patients.
Recurrence Rate: The overall recurrence rate of intracranial dural arteriovenous fistulas (DAVFs) after initial angiographic cure was 8.0%, with estimated recurrence rates of 13.9% at 36 months and 24.1% at 105 months; the annual recurrence risk was 6.2%.
Types of Recurrence: DAVF recurrence can be classified as in situ recurrence (at the original site) or remote site recurrence (at a different location); both are closely linked to unresolved venous hypertension and previously masked portions of the fistula.
Timing of Recurrence: Most recurrence events (76.6%) occurred within 15 months after initial cure, but delayed recurrences were observed, including cases more than 3 years and up to 10 years later.
Risk Factors: Key risk factors for recurrence included age younger than 45 years, transverse–sigmoid sinus location, multiple fistulae, pial arterial supply, and venous congestion.
Borden Classification: Recurrence was more frequently observed in Borden type II DAVFs, whereas Borden type III DAVFs had a lower recurrence rate when complete occlusion of the proximal draining vein was achieved.
Treatment Implications: Almost all recurrences occurred after endovascular therapy, highlighting the importance of ensuring complete occlusion of the draining vein to minimize recurrence risk.
Clinical Symptoms: There was no clear correlation between clinical symptoms and DAVF recurrence; many recurrences were asymptomatic, emphasizing the need for routine angiographic follow-up.
Follow-Up Recommendation: All patients with cured DAVFs, especially those with identified risk factors, should undergo angiographic follow-up beyond 1 year to detect and manage possible recurrences.




















You must be logged in to post a comment.